299 related articles for article (PubMed ID: 16565470)
21. [Molecular imaging of histamine receptors in the human brain].
Tashiro M; Yanai K
Brain Nerve; 2007 Mar; 59(3):221-31. PubMed ID: 17370648
[TBL] [Abstract][Full Text] [Related]
22. Molecular aspects of the histamine H3 receptor.
Bongers G; Bakker RA; Leurs R
Biochem Pharmacol; 2007 Apr; 73(8):1195-204. PubMed ID: 17276412
[TBL] [Abstract][Full Text] [Related]
23. Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
[TBL] [Abstract][Full Text] [Related]
24. Model of a specific human histamine H3 receptor (hH3R) binding pocket suitable for virtual drug design.
Schlegel B; Stark H; Sippl W; Höltje HD
Inflamm Res; 2005 Apr; 54 Suppl 1():S50-1. PubMed ID: 15928832
[No Abstract] [Full Text] [Related]
25. Histamine H3 receptor as a drug discovery target.
Berlin M; Boyce CW; Ruiz Mde L
J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
[No Abstract] [Full Text] [Related]
26. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
Geldenhuys WJ; Van der Schyf CJ
Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
[TBL] [Abstract][Full Text] [Related]
27. Histamine H3 receptor function and ligands: recent developments.
Singh M; Jadhav HR
Mini Rev Med Chem; 2013 Jan; 13(1):47-57. PubMed ID: 22931528
[TBL] [Abstract][Full Text] [Related]
28. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.
Esbenshade TA; Browman KE; Bitner RS; Strakhova M; Cowart MD; Brioni JD
Br J Pharmacol; 2008 Jul; 154(6):1166-81. PubMed ID: 18469850
[TBL] [Abstract][Full Text] [Related]
29. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
Medhurst AD; Briggs MA; Bruton G; Calver AR; Chessell I; Crook B; Davis JB; Davis RP; Foley AG; Heslop T; Hirst WD; Medhurst SJ; Ociepka S; Ray A; Regan CM; Sargent B; Schogger J; Stean TO; Trail BK; Upton N; White T; Orlek B; Wilson DM
Biochem Pharmacol; 2007 Apr; 73(8):1182-94. PubMed ID: 17276409
[TBL] [Abstract][Full Text] [Related]
30. Histamine and schizophrenia.
Arrang JM
Int Rev Neurobiol; 2007; 78():247-87. PubMed ID: 17349864
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic approach of histamine H3 receptors in obesity.
Masaki T; Yoshimatsu H
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):238-40. PubMed ID: 18221234
[TBL] [Abstract][Full Text] [Related]
32. Histamine H3-receptor isoforms.
Bakker RA
Inflamm Res; 2004 Oct; 53(10):509-16. PubMed ID: 15597144
[TBL] [Abstract][Full Text] [Related]
33. Histamine H3 receptor antagonists ameliorate attention deficit/hyperactivity disorder-like behavioral changes caused by neonatal habenula lesion.
Kim YJ; Goto Y; Lee YA
Behav Pharmacol; 2018 Feb; 29(1):71-78. PubMed ID: 28863002
[TBL] [Abstract][Full Text] [Related]
34. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
35. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
[TBL] [Abstract][Full Text] [Related]
36. Recent medicinal chemistry of the histamine H3 receptor.
Letavic MA; Barbier AJ; Dvorak CA; Carruthers NI
Prog Med Chem; 2006; 44():181-206. PubMed ID: 16697898
[No Abstract] [Full Text] [Related]
37. Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.
Fox GB; Esbenshade TA; Pan JB; Browman KE; Zhang M; Ballard ME; Radek RJ; Miner H; Bitner RS; Krueger KM; Yao BB; Faghih R; Rueter LE; Komater VA; Drescher KU; Buckley MJ; Sullivan JP; Cowart MD; Decker MW; Hancock AA
Inflamm Res; 2005 Apr; 54 Suppl 1():S23-4. PubMed ID: 15928819
[No Abstract] [Full Text] [Related]
38. [The histaminergic system: a target for innovative treatments of cognitive deficits].
Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
[TBL] [Abstract][Full Text] [Related]
39. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Semple G; Ren A; Pereira G; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Lorea J; Grottick AJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):4133-6. PubMed ID: 18554904
[TBL] [Abstract][Full Text] [Related]
40. [The histamine H(3) receptor: a target for new drugs].
Arrang JM
Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
